Current Treatment Options for Metastatic Hormone-Sensitive Prostate Cancer

Current Treatment Options for Metastatic Hormone-Sensitive Prostate Cancer

The possible treatments options for metastatic hormone-sensitive prostate cancer (mHSPC) have dramatically increased during the last years. The old backbone, which androgen-deprivation therapy (ADT) is the exclusive approach for hormone-naïve patients, has been disrupted. Despite the fact t...

Full description

Bibliographic Details
Main Authors:	Carlo Cattrini, Elena Castro, Rebeca Lozano, Elisa Zanardi, Alessandra Rubagotti, Francesco Boccardo, David Olmos
Format:	Article
Language:	English
Published:	MDPI AG 2019-09-01
Series:	Cancers
Subjects:	hormone-sensitive prostate cancer hormone-naïve prostate cancer docetaxel enzalutamide abiraterone acetate apalutamide radiotherapy
Online Access:	https://www.mdpi.com/2072-6694/11/9/1355

Similar Items

Hormonal Intensification Should Start at the Low-risk Stage in Metastatic Prostate Cancer
by: Seyed Behzad Jazayeri, et al.
Published: (2022-11-01)

Choice of treatment options for metastatic hormone-sensitive prostate cancer
by: R. A. Gafanov, et al.
Published: (2020-12-01)

A Cost-Effectiveness Analysis of Systemic Therapy for Metastatic Hormone-Sensitive Prostate Cancer
by: Winnie W. Y. Sung, et al.
Published: (2021-02-01)

A review of new hormonal therapies for prostate cancer in black men: is there enough data?
by: Matthias E. Meunier, et al.
Published: (2021-01-01)

Evaluation of Cognitive Function in Trials Testing New-Generation Hormonal Therapy in Patients with Prostate Cancer: A Systematic Review
by: Laura Marandino, et al.
Published: (2020-09-01)

Current management of metastatic castration-sensitive prostate cancer
by: Adam Kessel, et al.
Published: (2021-01-01)

Trends in the Use of Second-Generation Androgen Receptor Axis Inhibitors for Metastatic Hormone-Sensitive Prostate Cancer and Clinical Factors Predicting Biological Recurrence
by: Keita Nakane, et al.
Published: (2023-05-01)

A Phase 1b Adaptive Androgen Deprivation Therapy Trial in Metastatic Castration Sensitive Prostate Cancer
by: Jingsong Zhang, et al.
Published: (2022-10-01)

Prognostic Impact of Sarcopenia in Patients with Metastatic Hormone-Sensitive Prostate Cancer
by: Ji Hyun Lee, et al.
Published: (2021-12-01)

Second-Generation Antiandrogen Therapy Radiosensitizes Prostate Cancer Regardless of Castration State through Inhibition of DNA Double Strand Break Repair
by: Mohamed E. Elsesy, et al.
Published: (2020-08-01)

Cost-effectiveness analysis of cabazitaxel for metastatic castration resistant prostate cancer after docetaxel and androgen-signaling-targeted inhibitor resistance
by: Peng-Fei Zhang, et al.
Published: (2021-01-01)

Addressing the risk and management of cardiometabolic complications in prostate cancer patients on androgen deprivation therapy and androgen receptor axis-targeted therapy: consensus statements from the Hong Kong Urological Association and the Hong Kong Society of Uro-Oncology
by: Darren M. C. Poon, et al.
Published: (2024-01-01)

Outcomes Management in a Real-World Evidence Context: The Case of Abiraterone and Enzalutamide in the Treatment of Metastatic Castration-Resistant Prostate Cancer
by: Pedro Cardoso, et al.
Published: (2020-05-01)

Abiraterone acetate for early stage metastatic prostate cancer: patient selection and special considerations
by: Castellan P, et al.
Published: (2018-12-01)

Assessment of androgen receptor signaling inhibitors therapy in metastatic hormone-sensitive prostate cancer
by: Jukapun Yoodee, et al.
Published: (2022-11-01)

Utilization Trends of Novel Hormonal Agents in Metastatic Castration-Resistant Prostate Cancer in Quebec
by: Jason Hu, et al.
Published: (2022-11-01)

Novel hormonal therapies in the management of advanced prostate cancer: extrapolating Asian findings to Southeast Asia
by: Teng Aik Ong, et al.
Published: (2023-01-01)

Second-Generation Androgen Receptor Antagonists as Hormonal Therapeutics for Three Forms of Prostate Cancer
by: Pravien Rajaram, et al.
Published: (2020-05-01)

Survival outcomes and prognostic factors for first-line abiraterone acetate or enzalutamide in patients with metastatic castration-resistant prostate cancer
by: Chi-Shin Tseng, et al.
Published: (2023-06-01)

Enzalutamide versus Abiraterone Acetate as first-line treatment of castration resistant metastatic prostate cancer in geriatric (≥75) patients
by: Ali Alkan, et al.
Published: (2021-09-01)

Making the Case for Autophagy Inhibition as a Therapeutic Strategy in Combination with Androgen-Targeted Therapies in Prostate Cancer
by: Ahmed M. Elshazly, et al.
Published: (2023-10-01)

Mechanisms of Resistance to Second-Generation Antiandrogen Therapy for Prostate Cancer: Actual Knowledge and Perspectives
by: Francesco Pinto, et al.
Published: (2022-04-01)

Systemic and tumor-directed therapy for oligometastatic prostate cancer: study protocol for a phase II trial for veterans with de novo oligometastatic disease
by: Neil R. Parikh, et al.
Published: (2019-04-01)

Abiraterone acetate and docetaxel with androgen deprivation therapy in high-volume metastatic hormone-sensitive prostate cancer in China: an indirect treatment comparison and cost analysis
by: Xin Hu, et al.
Published: (2019-12-01)

Sequential therapy with darolutamide in patients with non‐metastatic castration‐resistant prostate cancer resistant to enzalutamide or apalutamide
by: Saizo Fujmoto, et al.
Published: (2023-02-01)

Progress in A Real-world Study of Abiraterone Acetate Versus Docetaxel in Patients with Metastatic Hormone-sensitive Prostate Cancer
by: MA Dongsheng, et al.
Published: (2023-05-01)

RNA Biomarkers as a Response Measure for Survival in Patients with Metastatic Castration-Resistant Prostate Cancer
by: Emmy Boerrigter, et al.
Published: (2021-12-01)

Optimisation of second line antihormonal treatment for castration resistant metastatic prostate cancer
by: Kullmann Tamás, et al.
Published: (2022-04-01)

Influence of abiraterone and enzalutamide on body composition in patients with metastatic castration resistant prostate cancer
by: Stefanie Fischer, et al.
Published: (2020-01-01)

Renal and Cardiovascular Toxicities by New Systemic Treatments for Prostate Cancer
by: Giuseppe Saltalamacchia, et al.
Published: (2020-07-01)

The LACOG-0415 phase II trial: abiraterone acetate and ADT versus apalutamide versus abiraterone acetate and apalutamide in patients with advanced prostate cancer with non-castration testosterone levels
by: Gustavo Werutsky, et al.
Published: (2019-05-01)

The evolution of prostate cancer therapy: targeting the androgen receptor (AR)
by: Jeanny B. Aragon-Ching
Published: (2014-10-01)

Therapeutic Resistance Models and Treatment Sequencing in Advanced Prostate Cancer
by: Zachary A. Schaaf, et al.
Published: (2023-11-01)

New developments in the treatment of castration resistant prostate cancer
by: Roxanne Wadia, et al.
Published: (2014-08-01)

Real-life data of abiraterone acetate and enzalutamide treatment in post-chemotherapy metastatic castration-resistant prostate cancer in Poland
by: Dawid Sigorski, et al.
Published: (2023-04-01)

Real‐world first‐line systemic therapy patterns in metastatic castration‐resistant prostate cancer
by: Angelyn Anton, et al.
Published: (2022-05-01)

Plasmatic MicroRNAs and Treatment Outcomes of Patients with Metastatic Castration-Resistant Prostate Cancer: A Hospital-Based Cohort Study and In Silico Analysis
by: Jani Silva, et al.
Published: (2023-05-01)

Abiraterone In Vitro Is Superior to Enzalutamide in Response to Ionizing Radiation
by: Timothy C. Wright, et al.
Published: (2021-07-01)

Improving quality of life in metastatic castration-resistant prostate cancer: the role of androgen receptor axis-targeted agents
by: Monika Kuzma, et al.
Published: (2023-07-01)

Direct medical costs of using enzalutamide or abiraterone in chemotherapy-naïve patients with metastatic castration resistant prostate cancer
by: N. A. Avxentyev, et al.
Published: (2019-01-01)